GBM Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAdvancing BLA review and completed prelicensure inspections represent meaningful progress toward a potential regulatory milestone. If approval is secured, Inovio could convert its lead program from development-stage activity into a commercial opportunity and establish a foundation for broader pipeline development.
Platform ValidationPositive pivotal results from a partner support the broader relevance of Inovio’s DNA medicine platform beyond its lead candidate. External clinical validation can strengthen partnering credibility, improve the platform’s development prospects, and support future opportunities across oncology and infectious or rare diseases.
Cost Discipline And RunwayLower operating expenses show tangible cost discipline, while the financing provides additional resources to advance regulatory and launch activities. Together, these actions extend the time available to pursue INO-3.11k and other programs, although the benefit depends on maintaining spending control.
Bears Say
Unprofitable Operating ModelThe company has not yet demonstrated a self-sustaining commercial model: revenue has contracted to effectively zero while operating expenses continue to produce substantial losses. This leaves future progress dependent on clinical milestones, partnerships, approvals, or new financing rather than internally generated earnings.
Cash Burn And Balance Sheet PressurePersistent operating cash burn limits financial flexibility and requires continued access to capital while programs remain in development. The weakened equity base and higher debt-to-equity ratio increase financing sensitivity, making it harder to absorb delays, fund launch needs, or advance multiple programs simultaneously.
Regulatory Approval UncertaintyThe lead program still faces material regulatory uncertainty despite progress in review and inspections. An unfavorable decision on accelerated approval or confirmatory requirements could delay commercialization, increase development costs, and weaken the near-term value of the company’s principal pathway to revenue.
Inovio Pharmaceuticals News
GBM FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is CHF95.08M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 27 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -CHF0.058 earnings per share for the quarter, beating the consensus estimate of -CHF0.181 by CHF0.122.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Inovio Pharmaceuticals have?
Currently, no data Available
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -CHF0.058 in its last earnings report, beating expectations of -CHF0.181. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:GBM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF2.64 (― Upside)
CHF2.64 (― Upside)
Blogger Sentiment
Bullish
CH:GBM Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.59%
12-Months-Change
Fundamentals
Return on Equity
-1005.80%
Trailing 12-Months
Asset Growth
-27.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
GBM Company Deck
GBM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.View all CH:GBM earnings summaries